EIS Eczacibasi Ilac, TRAECILC91E0

EIS Eczacibasi Ilac stock: Nine-month review details portfolio structure

Published on 10/30/2026 at 01:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
EIS Eczacibasi Ilac stock is covered in a nine-month operating review focused on its investment portfolio and governance. The company has no direct production activities.

Ownership and portfolio profile

  • EIS Eczacibasi Ilac operates as an investment holding company without direct production activities.
  • The review describes pharmaceutical, real estate, IT, foreign trade and ceramics investments.
  • The company trades on Borsa Istanbul's Yildiz Pazar under the ticker ECILC.
EIS Eczacibasi Ilac, TRAECILC91E0, Illustration mit AI erstellt.

EIS Eczacibasi Ilac's board operating review for the nine-month period ended 30 September 2026 highlighted the company's role as an investment holding company rather than a direct producer. The details were reported by TipRanks on 27 October 2026.

Holding company structure

The review describes EIS Eczacibasi Ilac as a non-producing holding company with investments spanning pharmaceuticals, real estate development, information technology, foreign trade and ceramics. Its portfolio includes subsidiaries such as Gensenta Ilac, EIP Eczacibasi Ilac Pazarlama and VitrA Karo.

The company also holds a 37.28% non-controlling interest in Eczacibasi Holding. According to the review, that stake is presented as a financial asset measured at fair value through other comprehensive income, while EIS Eczacibasi Ilac does not exercise guiding influence over Eczacibasi Holding.

Ownership and trading profile

The operating review discusses changes in shareholder composition between December 2025 and September 2026. It also describes a publicly traded portion of just over 22%, equal voting rights for bearer shares and the absence of privileged shares or share buybacks. The company's capital was reported at TRY 685.26 million.

For investors, the information clarifies that the stock represents exposure to a diversified investment portfolio rather than a single operating pharmaceutical business. The report also identifies Eczacibasi Gayrimenkul Gelistirme ve Yatirim as a wholly controlled subsidiary and notes near-total control of key pharmaceutical and marketing units.

EIS Eczacibasi Ilac at a glance

  • ISIN: TRAECILC91E0
  • Ticker: ECILC
  • Exchange: Borsa Istanbul, Yildiz Pazar
  • Reporting period: Nine months ended 30 September 2026
  • Business model: Investment holding company without direct production activities
  • Capital: TRY 685.26 million
  • Free float: Just over 22%

The broader Turkish market backdrop can be followed through current BIST 100 market coverage.

More updates are available in more news and analyses on EIS Eczacibasi Ilac stock.

Disclaimer...
en | TRAECILC91E0 | EIS ECZACIBASI ILAC | boerse | 70431299 |